S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The Ignored EV Story Few Investors Know About (Ad)
Dollar General May Create an Opportunity for Patient Investors
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
The Ignored EV Story Few Investors Know About (Ad)
SunCar Technology Stock Overheats...Will it Rise Again?
How major US stock indexes fared Monday 6/5/2023
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The Ignored EV Story Few Investors Know About (Ad)
Dollar General May Create an Opportunity for Patient Investors
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
The Ignored EV Story Few Investors Know About (Ad)
SunCar Technology Stock Overheats...Will it Rise Again?
How major US stock indexes fared Monday 6/5/2023
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The Ignored EV Story Few Investors Know About (Ad)
Dollar General May Create an Opportunity for Patient Investors
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
The Ignored EV Story Few Investors Know About (Ad)
SunCar Technology Stock Overheats...Will it Rise Again?
How major US stock indexes fared Monday 6/5/2023
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The Ignored EV Story Few Investors Know About (Ad)
Dollar General May Create an Opportunity for Patient Investors
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
The Ignored EV Story Few Investors Know About (Ad)
SunCar Technology Stock Overheats...Will it Rise Again?
How major US stock indexes fared Monday 6/5/2023
NASDAQ:KTRA

Kintara Therapeutics (KTRA) Stock Forecast, Price & News

$3.15
-0.32 (-9.22%)
(As of 06/5/2023 ET)
Compare
Today's Range
$3.13
$3.36
50-Day Range
$2.77
$4.36
52-Week Range
$2.70
$20.00
Volume
17,475 shs
Average Volume
22,259 shs
Market Capitalization
$5.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

KTRA stock logo

About Kintara Therapeutics (NASDAQ:KTRA) Stock

Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Receive KTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KTRA Stock News Headlines

The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
The Ignored EV Story Few Investors Know About
Lithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.
10 Pump and Dump Stocks Hedge Funds Like
See More Headlines

KTRA Price History

KTRA Company Calendar

Last Earnings
5/11/2023
Today
6/06/2023
Fiscal Year End
6/30/2023
Next Earnings (Estimated)
9/26/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KTRA
Employees
4
Year Founded
N/A

Profitability

Net Income
$-22,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.58) per share

Miscellaneous

Free Float
1,619,000
Market Cap
$5.32 million
Optionable
Not Optionable
Beta
0.93

Key Executives

  • Robert E. Hoffman
    Chairman, President & Chief Executive Officer
  • Greg A. Johnson
    Head-Operations
  • Scott Praill
    Chief Financial Officer & Secretary
  • Dennis M. Brown
    Chief Scientific Officer













KTRA Stock - Frequently Asked Questions

Should I buy or sell Kintara Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kintara Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" KTRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KTRA, but not buy additional shares or sell existing shares.
View KTRA analyst ratings
or view top-rated stocks.

How have KTRA shares performed in 2023?

Kintara Therapeutics' stock was trading at $6.89 at the start of the year. Since then, KTRA stock has decreased by 54.3% and is now trading at $3.15.
View the best growth stocks for 2023 here
.

When is Kintara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 26th 2023.
View our KTRA earnings forecast
.

How were Kintara Therapeutics' earnings last quarter?

Kintara Therapeutics, Inc. (NASDAQ:KTRA) posted its earnings results on Thursday, May, 11th. The company reported ($1.94) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $1.84.

When did Kintara Therapeutics' stock split?

Kintara Therapeutics's stock reverse split on Monday, November 14th 2022. The 1-50 reverse split was announced on Monday, November 14th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 14th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Kintara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kintara Therapeutics investors own include Ampio Pharmaceuticals (AMPE), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Fortress Biotech (FBIO), Immunic (IMUX), Miragen Therapeutics (MGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN).

What is Kintara Therapeutics' stock symbol?

Kintara Therapeutics trades on the NASDAQ under the ticker symbol "KTRA."

Who are Kintara Therapeutics' major shareholders?

Kintara Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Susquehanna International Group LLP (0.63%). Insiders that own company stock include Anthony Scott Praill, Laura L Johnson and Saiid Zarrabian.
View institutional ownership trends
.

How do I buy shares of Kintara Therapeutics?

Shares of KTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kintara Therapeutics' stock price today?

One share of KTRA stock can currently be purchased for approximately $3.15.

How much money does Kintara Therapeutics make?

Kintara Therapeutics (NASDAQ:KTRA) has a market capitalization of $5.32 million. The company earns $-22,660,000.00 in net income (profit) each year or ($11.04) on an earnings per share basis.

How can I contact Kintara Therapeutics?

Kintara Therapeutics' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.kintara.com. The company can be reached via phone at (858) 350-4364, via email at ir@delmarpharma.com, or via fax at 604-608-5685.

This page (NASDAQ:KTRA) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -